Lexicon Pharmaceuticals (LXRX) Competitors $0.73 +0.06 (+9.27%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX vs. ZBIO, VSTM, RIGL, XOMA, VNDA, EBS, CDXS, SGMO, RGLS, and IRWDShould you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Zenas Biopharma (ZBIO), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Codexis (CDXS), Sangamo Therapeutics (SGMO), Regulus Therapeutics (RGLS), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Lexicon Pharmaceuticals vs. Zenas Biopharma Verastem Rigel Pharmaceuticals XOMA Vanda Pharmaceuticals Emergent BioSolutions Codexis Sangamo Therapeutics Regulus Therapeutics Ironwood Pharmaceuticals Lexicon Pharmaceuticals (NASDAQ:LXRX) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Do insiders and institutionals have more ownership in LXRX or ZBIO? 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer LXRX or ZBIO? Lexicon Pharmaceuticals received 482 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 64.02% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48464.02% Underperform Votes27235.98% Zenas BiopharmaOutperform Votes2100.00% Underperform VotesNo Votes Does the media prefer LXRX or ZBIO? In the previous week, Zenas Biopharma had 24 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 29 mentions for Zenas Biopharma and 5 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.83 beat Zenas Biopharma's score of 0.03 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LXRX or ZBIO more profitable? Zenas Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Zenas Biopharma's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% Zenas Biopharma N/A N/A N/A Do analysts prefer LXRX or ZBIO? Lexicon Pharmaceuticals presently has a consensus price target of $3.67, suggesting a potential upside of 401.73%. Zenas Biopharma has a consensus price target of $40.00, suggesting a potential upside of 245.42%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Zenas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, LXRX or ZBIO? Zenas Biopharma has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Zenas Biopharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$31.08M5.79-$177.12M-$0.64-1.14Zenas Biopharma$5M96.81-$148.39M-$3.55-3.26 SummaryLexicon Pharmaceuticals and Zenas Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXRX vs. The Competition Export to ExcelMetricLexicon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$179.95M$6.89B$5.57B$7.83BDividend YieldN/A3.06%5.11%4.21%P/E Ratio-0.977.4422.4418.48Price / Sales5.79242.73394.10103.59Price / CashN/A65.8538.1834.62Price / Book1.926.516.774.25Net Income-$177.12M$143.21M$3.22B$248.23M7 Day Performance3.90%1.98%1.48%0.89%1 Month Performance57.47%6.89%3.99%3.53%1 Year Performance-55.71%-2.52%16.20%5.08% Lexicon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXRXLexicon Pharmaceuticals3.5253 of 5 stars$0.73+9.3%$3.67+401.7%-52.5%$179.95M$31.08M-0.97140Upcoming EarningsNews CoverageZBIOZenas BiopharmaN/A$9.45+5.9%$40.00+323.3%N/A$395.00M$5M-2.66N/AGap DownVSTMVerastem3.1278 of 5 stars$6.06+5.6%$13.89+129.2%-24.9%$312.03M$10M-1.9050Upcoming EarningsAnalyst RevisionRIGLRigel Pharmaceuticals2.5977 of 5 stars$17.00+0.9%$36.80+116.5%+86.3%$303.74M$179.28M121.44160Upcoming EarningsPositive NewsGap DownXOMAXOMA4.0289 of 5 stars$22.20+4.8%$59.67+168.8%-5.1%$265.36M$10.22M-6.3810Upcoming EarningsPositive NewsVNDAVanda Pharmaceuticals4.1104 of 5 stars$4.29-0.9%$16.50+284.6%-5.3%$250.18M$198.77M-13.41290Upcoming EarningsShort Interest ↑Positive NewsEBSEmergent BioSolutions4.0215 of 5 stars$4.50-2.6%$14.33+218.5%+183.5%$244.52M$1.01B-1.102,420Upcoming EarningsGap DownCDXSCodexis3.505 of 5 stars$2.15+1.9%$8.33+287.6%-21.0%$178.10M$59.35M-2.47250News CoveragePositive NewsSGMOSangamo Therapeutics1.5742 of 5 stars$0.75+6.8%$5.17+585.9%+50.0%$169.27M$57.80M-1.00480RGLSRegulus Therapeutics1.953 of 5 stars$1.99-3.4%$12.75+540.7%+247.0%$131.82MN/A-1.8630Analyst ForecastOptions VolumeNews CoveragePositive NewsGap UpTrading HaltedIRWDIronwood Pharmaceuticals4.3873 of 5 stars$0.73+1.1%$4.78+551.1%-88.0%$118.87M$351.41M-24.49220Gap Down Related Companies and Tools Related Companies ZBIO Alternatives VSTM Alternatives RIGL Alternatives XOMA Alternatives VNDA Alternatives EBS Alternatives CDXS Alternatives SGMO Alternatives RGLS Alternatives IRWD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXRX Stock Free LXRX Stock Alerts